Ani Pharmaceuticals Inc. (ANIP)
ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
ANI Pharmaceuticals, Inc. (ANIP) Q3 2025 Earnings Call Transcript
ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2025 Earnings Call November 7, 2025 8:30 AM EST Company Participants Nikhil Lalwani - President, CEO & Director Christopher Mutz - Senior Vp & Head of Rare Disease Stephen Carey - Senior VP of Finance & CFO Conference Call Participants Yuchen Ding - Jefferies LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Daniel Krizay - Guggenheim Securities, LLC, Research Division Gary Nachman - Raymond James & Associates, Inc., Research Division Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Leszek Sulewski - Truist Securities, Inc., Research Division Presentation Operator Good morning, everyone, and welcome to today's ANI Pharmaceuticals Third Quarter 2025 Earnings Results Call.
Compared to Estimates, ANI (ANIP) Q3 Earnings: A Look at Key Metrics
Although the revenue and EPS for ANI (ANIP) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
ANI Pharmaceuticals: Strong Buy On Rare Disease Growth, Record Of Beating Estimates
In my opinion, ANI Pharmaceuticals should beat earnings and revenue estimates for the 13th consecutive quarter. Purified Cortrophin sales should lead the way. ANIP should announce approval and marketing of two new drugs, Inzirqo and Tezruly. Updated sales from Purified Cortophin Gel, Inzirqo and Tezruly could result in ANIP raising 2025 guidance for the 3rd time this year, in my view.
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
